Amneal Pharmaceuticals Inc
NYSE:AMRX
Relative Value
The Relative Value of one AMRX stock under the Base Case scenario is 17.89 USD. Compared to the current market price of 6.06 USD, Amneal Pharmaceuticals Inc is Undervalued by 66%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
AMRX Competitors Multiples
Amneal Pharmaceuticals Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
Amneal Pharmaceuticals Inc
NYSE:AMRX
|
1.9B USD | 0.8 | -22.2 | 8.8 | 16.1 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
US |
Eli Lilly and Co
NYSE:LLY
|
738.6B USD | 21.6 | 140.9 | 63.6 | 73 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
3.9T DKK | 16.9 | 47 | 34.3 | 37.4 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
380.8B USD | 4.5 | 10.8 | 12.2 | 15.9 | ||
US |
Merck & Co Inc
NYSE:MRK
|
334B USD | 5.6 | 915.2 | 45.4 | 88.7 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
165.5B GBP | 4.6 | 35.1 | 138.9 | 222.8 | ||
CH |
Roche Holding AG
SIX:ROG
|
183.1B CHF | 3.1 | 15.9 | 8.8 | 10.4 | ||
CH |
Novartis AG
SIX:NOVN
|
178.6B CHF | 4.2 | 13.3 | 9.8 | 16.1 | ||
US |
Pfizer Inc
NYSE:PFE
|
156.7B USD | 2.7 | 73.9 | 11.1 | 16.6 |